Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..."
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... the development of bleeding during anticoagulant therapy with direct oral anticoagulants (DOAC). Material ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
 
Vol 14, No 6 (2018) Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding Abstract  PDF (Eng)  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin
"... anticoagulants (DOACs) inhibitors, as antidotes for DOAC when stopping life-threatening bleeding. DOAC therapy ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
"... , антикоагулянтная терапия, варфарин, апиксабан, ривароксабан, дабигатран. Рациональная фармакотерапия в кардиологии ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..."
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
"... , апиксабан. РФК 2011;7(5):628-636 Antithrombotic therapy in atrial fibrillation: recent approaches and near ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... медицинской этики. Ключевые слова: фибрилляция предсердий, дабигатран, апиксабан, ривароксабан, риск ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... , ривароксабан, апиксабан, атеросклероз почечных артерий. Для цитирования: Даабуль И.С., Соколова А.А., Напалков ..."
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 14, No 4 (2018) Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing Abstract  similar documents
A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik
"... patients, including warfarin (39.5%), direct oral anticoagulants (DOAC) (46.5%) and low-molecular weight ..."
 
Vol 14, No 5 (2018) Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin
"... is on comparison of effectiveness and safety of NOACs based  on randomized clinical trials (RCT) and real-world ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 12, No 1 (2016) Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov
"... - ское испытание, ривароксабан, дабигатран, апиксабан, ВТЭО, новые пероральные антикоагулянты, новые ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... , апиксабан по сравнению с АСК при- водил к значимому снижению риска первой госпита- лизации пациентов с ФП в ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... –дабигатранаэтексилат, ингибиторы фактора Xa – ривароксабан и апиксабан. Совсем недавно к ним при- соединился эдоксабан ..."
 
Vol 12, No 4 (2016) Fighting with obesity: the "gold standard" and new horizons Abstract  similar documents
O. M. Drapkina, Yu. V. Dubolazova, S. A. Boytsov
"... Data of the World Health Organization and numerous clinical studies have shown a steady increase ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... ,0), что соответствовало средним показателям участников ключевых рандомизированных исследований апиксабана ..."
 
Vol 10, No 6 (2014) THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Abstract  similar documents
A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
"... данной группы: дабигатрана этексилат (Прадакса), ривароксабан (Ксарелто), апиксабан (Эликвис) (табл. 3 ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..."
 
Vol 6, No 4 (2010) CLOPIDOGREL PHARMACOGENETICS Abstract  similar documents
A. N. Meshkov
"... agents all over the world is clopidogrel, R2Y12-receptor blocker. It is shown that clopidogrel has ..."
 
Vol 13, No 1 (2017) AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
N. Yu. Shimohina, M. M. Petrova, A. A. Savchenko, M. S. Chernyaeva
"... According to the World Health Organization, anxiety and depressive disorders will be the second ..."
 
Vol 11, No 2 (2015) CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES: FOCUS ON ATRIAL FIBRILLATION Abstract  similar documents
V. N. Shishkova
"... фактора Xа – ривароксабан, апиксабан, эдоксабан. НОАК не тре- буют регулярного мониторинга коагуляции ..."
 
Vol 11, No 5 (2015) The role of peptide hormones (adiponectin, leptin, insulin) in the pathogenesis of atherosclerosis Abstract  similar documents
S. A. Smetnev, A. N. Meshkov
"... Currently, cardiovascular diseases (CVD) remain the main problem in the world and in Russia ..."
 
Vol 8, No 1 (2012) CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 1 Abstract  similar documents
V. V. Popov, N. A. Bulanov, G. G. Ivanov
"... among the cardiovascular diseases in the economically developed and developing countries of the world ..."
 
Vol 8, No 2 (2012) CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 Abstract  similar documents
V. V. Popov, N. A. Bulanov, G. G. Ivanov
"... among the cardiovascular diseases in the economically developed and developing countries of the world ..."
 
Vol 7, No 5 (2011) DIETARY FATTY ACIDS. EFFECTS ON THE RISK OF CARDIOVASCULAR DISEASES Abstract  similar documents
N. V. Perova, V. A. Metel'skaya, E. I. Sokolov, G. N. Shchukina, V. M. Fomina
"... The world publications data about the impact of consumption and the fatty acids ratio in consumed ..."
 
Vol 13, No 2 (2017) POSSIBILITIES OF ENHANCED EXTERNAL COUNTERPULSATION USING IN CLINICAL PRACTICE Abstract  similar documents
Z. A. Mamieva, A. S. Lishuta, Yu. N. Belenkov, E. V. Privalova, A. O. Yusupova, S. M. Rykova
"... ), which has long established itself throughout the world, are discussed in the article. Historical ..."
 
Vol 11, No 4 (2015) EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME Abstract  similar documents
A. V. Rudakova, N. V. Lomakin
"... use of apixaban compared with warfarin and acetyl- salicylic acid. Ration Pharmacother Cardiol 2014 ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
"... исследовании оценивались эффек- тивность и безопасность ривароксабана, апиксабана и дабигатрана в сравнении с ..."
 
Vol 13, No 2 (2017) ONCE AGAIN ABOUT THE HIERARCHY OF EVIDENCES IN MEDICINE OR WHETHER IT IS POSSIBLE TO CHOOSE THE MOST EFFECTIVE AND SAFE DRUG WITH THE HELP OF OBSERVATIONAL STUDIES Abstract  similar documents
S. Y. Martsevich, Yu. V. Lukina, N. P. Kutishenko
"... день таких пре- паратов на российском рынке три: дабигатран, рива- роксабан и апиксабан. Каждый из этих ..."
 
Vol 11, No 6 (2015) Analysis of the problem of low adherence of patients to attendance at outpatient clinics and cardiorehabilitation programs according to the data from published studies Abstract  similar documents
Yu. V. Semenova, N. P. Kutishenko, S. Yu. Martsevich
"... is a common and urgent issue all over the world. It can affect medication adherence, which is crucial ..."
 
Vol 13, No 5 (2017) ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT Abstract  similar documents
S. G. Kanorskii
"... to pharmacotherapy is important for the long-term effectiveness of any medication; however, in the "real world ..."
 
Vol 13, No 6 (2017) SMOKING AS A RISK FACTOR OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES: PREVALENCE, IMPACT ON PROGNOSIS, POSSIBLE SMOKING CESSATION STRATEGIES AND THEIR EFFECTIVENESS. Part 1. Smoking Prevalence and Impact on Prognosis Abstract  similar documents
O. D. Ostroumova, A. A. Izvekov, N. Yu. Voevodina
"... , for women – 5.6 years. Tobacco use is a risk factor for 6 of 8 main causes of death in the world: ischemic ..."
 
Vol 14, No 1 (2018) RESPONSIBLE SELF-CARE – THE FUNDAMENTAL PRINCIPLES AND PLACE IN THE MODERN RUSSIAN HEALTHCARE SYSTEM Abstract  similar documents
S. N. Tolpygina, S. Yu. Martsevich, A. V. Kontsevaya, O. M. Drapkina
"... for both patients and the health system. According to the World Health Organization "Promoting effective ..."
 
Vol 14, No 3 (2018) EMBOLIC MYOCARDIAL INFARCTION. EXPERIENCE IN DIAGNOSIS AND MANAGEMENT Abstract  similar documents
A. S. Shilova, E. M. Gilyarova, D. A. Andreev, D. Yu. Shchekochikhin, N. A. Novikova, M. Yu. Gilyarov
"... in the Russian Federation and around the world. Approximately, in up to 10% of patients with clinical diagnostic ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... верапамилом, дилтиаземом и эрит- ромицином. Например, в американской инструкции к апиксабану, который ..."
 
Vol 12, No 5 (2016) Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs Abstract  similar documents
S. Yu. Martsevich, N. P. Kutishenko
"... пероральных антикоагулянтов, появив- шихся в последнее время – дабигатран, ривароксабан или апиксабан (в ..."
 
Vol 9, No 5 (2013) PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
"... , апиксабан, эдокса- бан, бетриксабан, YM150). Эти препараты имеют предсказуемую фармакокинетику, что ..."
 
Vol 10, No 4 (2014) MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
E. A. Belikov, K. V. Davtyan, O. N. Tkacheva
"... » антикоагулянтные препараты (АК): ингибитор тромбина (дабигатран) и блокаторы фактора Ха (ривароксабан и апиксабан ..."
 
Vol 4, No 3 (2008) THE RUSSIAN DATA OF INTERNATIONAL ENDORSE REGISTER (EPIDEMIOLOGIC INTERNATIONAL DAY FOR THE EVALUATION OF PATIENTS AT RISK OF VENOUS THROMBOSIS IN ACUTE HOSPITAL CARE SETTING) Abstract  similar documents
V. A. Sulimov, S. M. Belentsov, N. I. Golovina, N. P. Dubrovnaja, K. P. Zhidkov, K. V. Yeliseyeva, P. O. Kazanchan, A. V. Redkin, G. V. Rodoman, I. L. Fridman, V. N. Shershnev
"... to АССР Recommendations 2004. It is more than 2 times less in comparison with world level (р<0 ..."
 
Vol 13, No 2 (2017) MODELS OF MAJOR ADVERSE CARDIAC EVENT RISK USING RESULTS OF EXERCISE STRESS ECHOCARDIOGRAPHY WITH NONINVASIVE CORONARY ARTERY FLOW ASSESSMENT IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
A. V. Zagatina, N. T. Zhuravskaya, S. A. Sayganov
"... of contractility disorders and coronary blood flow parameters during exercise tests in the world literature ..."
 
Vol 12, No 6 (2016) ROLE OF NON-DRUG THERAPIES OF METABOLIC SYNDROME: CHALLENGES AND PROSPECTS Abstract  similar documents
S. N. Strelkova, K. V. Ovsyannicov, N. I. Utkina
"... in the world. The urgency of the problem of the progression of abdominal obesity is not only in its high ..."
 
Vol 15, No 2 (2019) Cardiovascular medicine prices as an indicator of access to medicines and their rational use Abstract  similar documents
C M. Razzakova, L. E. Ziganshina
"... in Kazan using the World Health Organization and Health Action International (WHO/HAI) methodology ..."
 
Vol 15, No 4 (2019) Antimicrobial Treatment of Infective Endocarditis, Caused by Enterococcus Faecalis Abstract  PDF (Eng)  similar documents
E. V. Shikh, T. E. Morozova, V. N. Drozdov, N. B. Lazareva, D. A. Shatsky, T. B. Andrushchyshina, M. V. Lukina, O. A. Vartanova
"... . The incidence of IE morbidity is recorded in all countries of the world and in the Russian Federation more than ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... entered the Russian pharmaceutical market, among them: dabigatran, rivaroxaban and apixaban. These drugs ..."
 
Vol 10, No 4 (2014) FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW Abstract  similar documents
S. A. Zenin, A. V. Fedoseenko, O. V. Kononenko, O. V. Pyataeva
"... витамина К (Вар- фарин), дабигатрана этексилат (Прадакса), апиксабан (Эликвис) и ривароксабан (Ксарелто ..."
 
Vol 8, No 4 (2012) THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY Abstract  similar documents
M. Yu. Gilyarov
"... - phylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world ..."
 
Vol 13, No 4 (2017) FEATURES OF CEREBRAL HEMODYNAMICS AND MANIFESTATIONS OF HEPATIC ENCEPHALOPATHY IN CIRRHOSIS OF VIRAL ETIOLOGY AT DIFFERENT COMPENSATION STAGES WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION Abstract  similar documents
V. E. Kulikov, T. A. Emelina, O. G. Kazakova, K. V. Nikolaevа, M. E. Hapman, M. A. Tonеeva
"... to the recommendations of the Working group of the XI-th World Gastroenterology Congress. Results. Reduction ..."
 
Vol 7, No 1 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS Abstract  similar documents
M. Yu. Gilyarov, V. A. Sulimov
"... терапии при ФП пероральных ингибиторов Ха фак- тора апиксабана и ривароксабана. Однако апиксабан в ..."
 
Vol 13, No 2 (2017) APPROACHES TO ANTITHROMBOTIC THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. A. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... 2-3); дозе (МНО 2-3); НПА (TTR>70%) или апиксабан или прямой ингибитор или прямой ингибитор ..."
 
Vol 10, No 6 (2014) PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION Abstract  similar documents
N. V. Mikheeva, O. V. Reshetko, N. V. Furman
"... инсульта у больных как с пароксизмальной, так и с постоянной формой ФП: апиксабан (класс I; уровень доказа ..."
 
Vol 12, No 4 (2016) The use of oral anticoagulants in patients with atrial fibrillation: cohort study data Abstract  similar documents
O. V. Gaisenok, A. S. Leonov
"... . Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation ..."
 
Vol 8, No 3 (2012) RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
M. Yu. Gilyarov
"... антикоагулянтов (RE-LY - дабигатран против варфарина и ARISTOTLE -апиксабан против варфарина) следует отметить ..."
 
Vol 7, No 5 (2011) CONGRESS OF EUROPEAN SOCIETY OF CARDIOLOGY IN PARIS: WHAT PRACTICAL PHYSICIAN SHOULD TAKE FOR THE NOTES Abstract  similar documents
S. Yu. Martsevich
"... - тода больным назначали либо апиксабан, новый ан- тикоагулянт, относящийся к группе ингибиторов Ха-фак ..."
 
Vol 6, No 5 (2010) THE CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY 2010 IN STOCKHOLM: NEWS FOR PRACTITIONERS Abstract  similar documents
S. Yu. Martsevich
"... AVERROES изучали эффективность апиксабана — принимаемого внутрь, являющегося прямым ингибитором Ха-фактора ..."
 
Vol 9, No 2 (2013) CONCOR AM: NEW FIXED COMBINATION OF BISOPROLOL AND AMLODIPINE FOR EFFECTIVE BLOOD PRESSURE CONTROL Abstract  similar documents
статья Редакционная
"... early morning blood pressure in patients with hypertension. Prev Cardiol 2007;10:210–14. 12. World ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... , apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110(3):453-60. 17 ..."
 
Vol 12, No 2 (2016) SYSTEMATIC REVIEW AND META-ANALYSIS: PITFALLS OF METHODS Abstract  similar documents
Yu. V. Lukina, S. Yu. Martsevich, N. P. Kutishenko
"... the New Oral Antico- agulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
"... , ривароксабан и апиксабан), которые в настоящее время показаны (по- казания, регламентированные российской ..."
 
Vol 13, No 1 (2017) THE STUDY "REGISTER OF PATIENTS AFTER ACUTE STROKE (REGION)". PART 2. OUTPATIENT PROSPECTIVE REGISTER OF PATIENTS AFTER ACUTE STROKE (ACCORDING TO THE RESULTS OF THE PILOT PHASE OF THE STUDY) Abstract  PDF (Eng)  similar documents
S. А. Boytsov, M. M. Loukianov, S. S. Yakushin, S. Yu. Martsevich, L. V. Stakhovskaya, A. N. Vorobyev, A. V. Zagrebelnyy, N. P. Kutishenko, A. N. Kozminsky, K. A. Moseichuk, K. G. Pereverzeva, E. A. Pravkina, E. N. Belova, E. V. Kudryashov, A. D. Deev
"... ) in majority of developed countries of the world [1]. Stroke morbidity and mortality rates in Russia continue ..."
 
Vol 13, No 4 (2017) HEALTHCARE RESOURCES UTILIZATION AND TEMPORARY DISABILITY IN POPULATION AGED 50-64 ACCORDING TO THE EPIDEMIOLOGICAL ESSE-RF STUDY Abstract  PDF (Eng)  similar documents
A. V. Kontsevaya, Yu. A. Balanova, A. E. Imaeva, A. D. Deev, A. V. Kapustina, G. A. Muromtseva, S. E. Evstifeeva, S. A. Shalnova
 
Vol 1, No 2 (2005) SYSTOLIC BLOOD PRESSURE REDUCTION: DO ALL THE DRUGS HAVE THE SAME EFFICIENCY? Abstract  similar documents
S. V. Nedogoda
"... исходное САД, САД, мм рт.ст % CARE (Clinical Altace Real-world Efficacy) [10] Рамиприл 11 100 8 недель ..."
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract  similar documents
Article Editorial
"... , et al. Real-world evidence of stroke prevention in patients with non- valvular atrial fibrillation in ..."
 
Vol 12, No 3 (2016) ADVERSE EVENT OF DRUG THERAPY (THE FIRST RESULTS OF THE STUDY ACCORDING TO THE PROFILE OUTPATIENT REGISTER) Abstract  PDF (Eng)  similar documents
Yu. V. Lukina, N. A. Dmitrieva, A. V. Zakharova, A. V. Zagrebelnyy, N. P. Kutishenko, S. Yu. Martsevich
"... препаратов. Клиницист 2012; 3-4: 4-9). 18. Furberg CD., Pitt B. Withdrawal of cerivastatin from the world ..."
 
Vol 12, No 3 (2016) EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY Abstract  PDF (Eng)  similar documents
E. A. Ushkalova, O. N. Tkacheva, N. K. Runikhina, N. A. Chukhareva, A. Yu. Bevz
"... 1. World Health Organization. Global status report on noncommunicable diseases. WHO: Geneva; 2010. 2 ..."
 
Vol 12, No 5 (2016) Lung Function Parameters in Patients with Dilated Cardiomyopathy Complicated by Pulmonary Hypertension Abstract  similar documents
T. A. Abdullaev, Ya. R. Ahmatov, B. U. Mardanov, R. Sh. Bekbulatova
"... ., et al. Report of the 1995 World Organization International Society and Federation of Cardiology Task ..."
 
Vol 13, No 3 (2017) ANGIOSARCOMA OF THE HEART – CLINICAL CASE Abstract  similar documents
N. Yu. Karpova, M. A. Rashid, T. V. Kazakova, N. S. Chipigina, A. V. Aksenova, R. V. Ershov, Zh. I. Banova, E. M. Levin, A. A. Byshov, B. V. Uvarovskaya
"... ., Charitos C., et al. Primary right atrium angiosarcoma mimicking peri- carditis. World J SurgOncol. 2007 ..."
 
Vol 7, No 1-2 (2011): РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ Abstract  similar documents
, , , , , , , , , , , , , , , , ,
 
Vol 9, No 3 (2013) HOW TO STAND UP PLAGIARISM IN THE SCIENTIFIC MEDICAL PUBLICATIONS? Abstract  similar documents
R. G. Oganov, N. P. Kutishenko, D. A. Anitchkov
"... World Association of Medical Editors (WAME), плагиатом можно считать присвоение слов, идей или мыслей ..."
 
Vol 10, No 3 (2014) THE FIRST EXPERIENCE OF LEFT ATRIAL APPENDAGE OCCLUDING DEVICES IMPLANTATION FOR PREVENTION OF STROKE IN THE STATE RESEARCH CENTRE FOR PREVENTIVE MEDICINE Abstract  similar documents
K. V. Davtyan, O. N. Tkacheva, A. A. Kalemberg, S. N. Koretsky
"... fibrillation. NEJM 2011;365:883-91. 4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... Апиксабан × Варфарин × + Дабигатран × Ривароксабан × Эдоксабан × Антигипертензивные средства Аллискирен ..."
 
Vol 10, No 6 (2014) DIAGNOSIS AND TREATMENT OF PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA IN REAL OUTPATIENT PRACTICE (ACCORDING TO THE RECVASA REGISTRY) Abstract  similar documents
A. I. Ershova, A. N. Meshkov, S. S. Yakushin, M. M. Loukianov, K. A. Moseychuk, S. Yu. Martsevich, A. V. Zagrebelnyy, A. N. Vorobyev, K. G. Pereverzeva, E. A. Pravkina, A. N. Kozminskiy, S. A. Boytsov
"... гиперхолестеринемии в реальной практике Литература 1. World Health Organization. World Health Report 2002: Reducing ..."
 
Vol 10, No 4 (2014) DIAGNOSTICS, TREATMENT, ASSOCIATED CARDIOVASCULAR AND CONCOMITANT NON-CARDIAC DISEASES IN PATIENTS WITH DIAGNOSIS OF “ATRIAL FIBRILLATION” IN REAL OUTPATIENT PRACTICE (ACCORDING TO DATA OF REGISTRY OF CARDIOVASCULAR DISEASES, RECVASA) Abstract  PDF (Eng)  similar documents
M. M. Loukianov, S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, A. N. Vorobyev, A. V. Zagrebelnyy, M. S. Kharlap, K. G. Pereverzeva, E. A. Pravkina, S. E. Serdyuk, A. D. Deev, E. N. Kudryashov
"... of the world [1,2]. Atrial fibrillation (AF) is the most prevalent heart rhythm disturbance with inci- dence ..."
 
Vol 10, No 6 (2014) VALIDATION OF THE MACNEW QUESTIONNAIRE FOR THE ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ISHEMIC HEART DISEASE Abstract  PDF (Eng)  similar documents
N. V. Pogosova, A. A. Kursakov, I. H. Boycharov, S. Höfer, N. Oldridge
"... жизни при ИБС The World Health Organization (WHO) defines Quality of life as individuals’ perception ..."
 
Vol 12, No 2 (2016) CORRELATIONS OF DIFFERENT STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF ARTERIAL WALL WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE OF DIFFERENT AGE. PART 1 Abstract  PDF (Eng)  PDF (Eng)  similar documents
I. D. Strazhesko, O. N. Tkacheva, D. U. Akasheva, E. V. Dudinskaya, M. V. Agaltsov, A. S. Kruglikova, N. V. Brailova, V. S. Pykhtina, E. V. Plokhova, N. V. Sharashkina, O. Yu. Isaykina, V. A. Vygodin, S. A. Boytsov
"... (CVD) remain the leading cause of death throughout the world [1], that is why their primary prevention ..."
 
1 - 100 of 221 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)